RPRX

Royalty Pharma (RPRX)

About Royalty Pharma (RPRX)

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Details

Daily high
$38.66
Daily low
$37.83
Price at open
$38.52
52 Week High
$41.24
52 Week Low
$24.05
Market cap
16.5B
Dividend yield
2.28%
Volume
6.1M
Avg. volume
4.6M
P/E ratio
22.03

Royalty Pharma News

Details

Daily high
$38.66
Daily low
$37.83
Price at open
$38.52
52 Week High
$41.24
52 Week Low
$24.05
Market cap
16.5B
Dividend yield
2.28%
Volume
6.1M
Avg. volume
4.6M
P/E ratio
22.03